People: Neuralstem Inc (CUR.OQ)
Dr. Cristina Csimma is a Director of Neuralstem, Inc., since September 2017. She is also a Board Member and Member of the Compensation and Nominating and Corporate Governance Committees of Juniper Pharmaceuticals. She also serves on advisory boards including the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee; the Executive Oversight Board to the National Institutes of Health (NIH) NeuroNext Network; the External Oversight Committee of NIH Blueprint Neurotherapeutics Network, the Harvard and Brigham and Women’s Hospital MRCT Center External Advisory Board, the TREAT-NMD Advisory Committee for Therapeutics (TACT) and the Rockefeller University Robertson Therapeutic Development Fund Review Committee. She was previously the Executive Chair of the Board of Directors of Exonics Therapeutics, a Director of Vtesse (acquired in March 2017 by Sucampo Pharmaceuticals) and Cydan, where she was also President and founding CEO, the Vice President of Drug Development at Virdante Pharmaceuticals Inc (acquired by Momenta), Principal at Clarus Ventures LLC, and held roles in Clinical Development and Translational Research at Wyeth (now Pfizer), Genetics Institute and Dana Farber Cancer Institute. Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University. In selecting Dr. Csimma, the board took into account her vast experience in the pharmaceutical industry, including her successes in developing drugs for various diseases throughout her career.
|Total Annual Compensation,||--|
|Restricted Stock Award,||--|
|Long-Term Incentive Plans,||--|
|Fiscal Year Total,||--|